Alpha-1-Antitrypsin-Deficiency in COVID-19

Individual Treatment of COVID-19 by Application of Alpha-1-antitrypsin

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04799873

Acronym

CORSAAR-AAT

Enrollment

Registered

2021-03-16

Start date

2020-04-08

Completion date

2020-12-01

Last updated

2025-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

The blood concentrations of alpha-1-antitrypsin are monitored during COVID-19. The clinical course of patients that received AAT infusion for clinical indication is monitored.

Detailed description

The blood concentrations of alpha-1-antitrypsin are monitored during COVID-19. The clinical course of patients that received AAT infusion for clinical indication is monitored. Clinical outcomes, blood inflammatory markers, and virus load are monitored.

Interventions

DRUGAAT( Alpha 1 Antitrypsin)

AAT administration based on clinical indication

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 110 Years

Healthy volunteers

Inclusion criteria

* Infection with SARS-COV2 * Age over 18 years

Exclusion criteria

* Unability to consent * Invasive ventilation

Design outcomes

Primary

Measure	Time frame	Description
Clinical course	3 months	Disease course such as death, need for ICU treatment, ventilatory support or deterioration are monitored

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026